Good evening :)
Lupin Limited

Lupin Limited

LUPIN Share Price

NSE
₹1,980.301.72% (-34.70)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹90,557 cr, stock is ranked 129

Stock is 1.35x as volatile as Nifty

LUPIN Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

High

Strong financials and growth story over the years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹90,557 cr, stock is ranked 129

Stock is 1.35x as volatile as Nifty

LUPIN Performance & Key Metrics

LUPIN Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
17.394.020.91%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.366.070.47%

LUPIN Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
52%
Analysts have suggested that investors can buy this stock

from 33 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

LUPIN Company Profile

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Investor Presentation

View older View older 

Nov 3, 2026

PDF
View Older Presentations

LUPIN Similar Stocks (Peers)

Compare with peers Compare with peers 

LUPIN Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.15
36.15
1Y Return
8.21%
8.21%
Buy Reco %
93.55
93.55
PE Ratio
80.71
80.71
1Y Return
22.06%
22.06%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
147.36
147.36
1Y Return
143.12%
143.12%
Buy Reco %
61.54
61.54
PE Ratio
21.62
21.62
1Y Return
26.03%
26.03%
Buy Reco %
57.69
57.69
PE Ratio
27.42
27.42
1Y Return
11.75%
11.75%
Buy Reco %
67.74
67.74
Compare with Peers

LUPIN Sentiment Analysis

LUPIN Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

LUPIN Stock Summary · August 2026

Management delivered a strong quarter overall, highlighting record revenue and continued margin expansion even as it flagged near-term pressure in the U.S. Revenue from operations rose 32% year over year to INR 8,277 crores, while EBITDA excluding forex and other income increased 50% to INR 2,464 crores and EBITDA margin improved to 30%. Management stressed that growth was broad-based and marked the 16th consecutive quarter of year-on-year expansion, with India formulations rising 13.9% and India diabetes up 31.8%, helped by semaglutide and leadership in Huminsulin. Emerging markets also grew sharply, with Brazil, South Africa and the Philippines driving 52% growth. At the same time, the U.S. business faced intensified competition in Mirabegron and growing pressure in Tolvaptan, and management said revenue could soften over the next couple of quarters. They kept their full-year U.S. revenue guidance at USD 1.1 billion to USD 1.2 billion, while pointing to more than 50 planned U.S. launches over three years, including biosimilars, respiratory products and Apixaban, as the path to restoring U.S. growth from FY28 onward.

LUPIN Stock Growth Drivers
LUPIN Stock Growth Drivers
13
  • Record Quarterly Financial and Operating Momentum

    Lupin delivered a standout quarter with total revenue from operations above INR 8,000 crores and

  • Broad-Based Geographic Growth and India Outperformance

    The company’s growth was supported by broad geographic momentum, with ex-U.S. organic revenue rising more

LUPIN Stock Challenges
LUPIN Stock Challenges
6
  • U.S. revenue and margin pressure from rising competition

    The company’s near-term U.S. performance is expected to weaken after a strong first quarter as

  • Earnings drag from rising costs and weaker non-operating income

    Profitability is being pressured by a combination of higher operating expenses, lower other income, and

LUPIN Forecast

LUPIN Forecasts

Price

Revenue

Earnings

LUPIN

LUPIN

Income

Balance Sheet

Cash Flow

LUPIN Income Statement

LUPIN Income Statement

Loading...

Quarterjun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue5,668.115,715.025,821.425,724.086,347.387,137.517,282.227,615.378,407.217,954.06
Operating & Other expensessubtract4,359.364,332.374,411.814,345.964,541.104,706.185,332.245,120.425,827.365,782.85
Depreciation/Amortizationsubtract247.71256.92271.45393.18298.98316.77312.96446.79452.85485.90
Interest & Other Itemssubtract68.0170.8766.8989.1091.76107.59114.98120.16109.64105.71
Taxes & Other Itemssubtract191.72202.23216.11123.32196.51529.05346.49467.66602.36424.34
EPS17.5818.7018.7516.9326.7032.3625.7434.8330.9525.27

LUPIN Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Nov 3PDF
Aug 6PDF
Aug 6PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 7PDF
Nov 6PDF
Aug 6PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 15PDF
Feb 11PDF
Nov 7PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 4PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
 

LUPIN Stock Peers

LUPIN Past Performance & Peer Comparison

LUPIN Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Lupin Limited15.704.020.91%
Sun Pharmaceutical Industries Limited36.155.380.85%
Torrent Pharmaceuticals Ltd80.7110.100.72%
Laurus Labs Ltd147.3624.110.08%
ScreenerCompare valuation on Screener

LUPIN Stock Price Comparison

Compare LUPIN with any stock or ETF
Compare LUPIN with any stock or ETF
LUPIN
Loading...

LUPIN Holdings

LUPIN Shareholdings

LUPIN Promoter Holdings Trend

LUPIN Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

LUPIN Institutional Holdings Trend

LUPIN Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

LUPIN Shareholding Pattern

LUPIN Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.84%14.58%9.20%23.28%6.09%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

LUPIN Shareholding History

LUPIN Shareholding History

JunSepDec '25MarJunSep21.25%20.49%21.49%21.71%22.42%23.28%

Mutual Funds Invested in LUPIN

Mutual Funds Invested in LUPIN

No mutual funds holding trends are available

Top 5 Mutual Funds holding Lupin Limited




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.2545%1.13%-0.15%20/346 (-4)
1.0670%0.89%-0.07%23/94 (-1)
1.0028%2.48%-0.30%14/51 (-3)

Compare 3-month MF holding change on Screener

LUPIN Insider Trades & Bulk Stock Deals

LUPIN Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing LUPIN stock

smallcases containing LUPIN stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Lupin Limited

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

LUPIN's Wtg.
5.00%
5.00%
CAGR
17.94%

LUPIN Events

LUPIN Events

LUPIN Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LUPIN has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.89%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.89 every year

Dividends

Corp. Actions

Announcements

Legal Orders

LUPIN Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LUPIN has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.89%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.89 every year

LUPIN Upcoming Dividends

LUPIN Upcoming Dividends

No upcoming dividends are available

LUPIN Past Dividends

LUPIN Past Dividends

Cash Dividend

Ex DateEx DateJul 17, 2026

Final
Final | Div/Share: ₹18.00

Dividend/Share

₹18.00

Ex DateEx Date

Jul 17, 2026

Cash Dividend

Ex DateEx DateJul 25, 2025

Final
Final | Div/Share: ₹12.00

Dividend/Share

₹12.00

Ex DateEx Date

Jul 25, 2025

Cash Dividend

Ex DateEx DateJul 16, 2024

Final
Final | Div/Share: ₹8.00

Dividend/Share

₹8.00

Ex DateEx Date

Jul 16, 2024

Cash Dividend

Ex DateEx DateJul 14, 2023

Final
Final | Div/Share: ₹4.00

Dividend/Share

₹4.00

Ex DateEx Date

Jul 14, 2023

Cash Dividend

Ex DateEx DateJul 14, 2022

Final
Final | Div/Share: ₹4.00

Dividend/Share

₹4.00

Ex DateEx Date

Jul 14, 2022

LUPIN Stock News & Opinions

LUPIN Stock News & Opinions

Earnings
Earnings
Lupin Ltd consolidated sales down 5.25% on year in Q3FY2026, net profit fell 18.47%

Lupin Ltd share price gained 0.15% to Rs 2015.0. The Company's net profit dropped 18.47% to Rs 1155.3 crore, while revenue from operations eased by 5.25% to Rs 7785.52 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.14%. It has improved by 2.03% over last one week and crept higher by 1.77% in last one month while the market capitalization of Lupin Ltd has inched up 0.85% and 14.61% in the same period respectively. Profit before tax (PBT) of Lupin Ltd stood at Rs 1579.6 crore in Q3 FY26, tumbling by 21.29% year-on-year, and nosediving by 21.70% quarter-on-quarter. EBITDA came in at Rs 1918 crore, dropping 14.82% YoY and plunging by 17.32% sequentially. Total expenses slightly declined by 0.18% to Rs 6268.75 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1310.74 crore, slightly declining by 0.07% YoY, while employee benefits expense was at Rs 1423.58 crore, inching up 2.93% YoY. For the TTM ended FY26, revenue from operations jumped by 23.86% to Rs 27487.54 crore, while net profit soared by 61.98% to Rs 5355.47 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 529273% to Rs 8391.55 crore, and PBT witnessed a strong rise of 71.17% to Rs 6872.55 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7334.5 crore in FY26, as against Rs 2999.94 crore in FY25. Lupin Ltd ticked higher by 0.84% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 7.38% during the same period.

1 week agoCapital Market - Live
Earnings
Earnings
Lupin Ltd consolidated sales down 5.25% on year in Q3FY2026, net profit fell 18.47%

Lupin Ltd share price ticked higher by 0.77% to Rs 2012.0. The Company's net profit contracted by 18.47% to Rs 1155.3 crore, while revenue from operations softened by 5.25% to Rs 7785.52 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, rising 4.36%. It has improved by 1.84% over last one week and moved up slightly by 1.37% in last one month while the market capitalization of Lupin Ltd has marginally improved by 2.08% and 15.86% in the same period respectively. Profit before tax (PBT) of Lupin Ltd stood at Rs 1579.6 crore in Q3 FY26, plunging by 21.29% year-on-year, and tumbling by 21.70% quarter-on-quarter. EBITDA came in at Rs 1918 crore, dropping 14.82% YoY and nosediving by 17.32% sequentially. Total expenses marginally dropped 0.18% to Rs 6268.75 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1310.74 crore, slightly declining by 0.07% YoY, while employee benefits expense was at Rs 1423.58 crore, ticking higher by 2.93% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 23.86% to Rs 27487.54 crore, while net profit jumped 61.98% to Rs 5355.47 crore, compared to previous TTM. EBITDA jumped by 529273% to Rs 8391.55 crore, and PBT soared 71.17% to Rs 6872.55 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7334.5 crore in FY26, as against Rs 2999.94 crore in FY25. Lupin Ltd inched up 1.32% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 8.41% during the same period.

1 week agoCapital Market - Live
Corporate
Corporate
Lupin Limited appoints Akhil Gupta as Independent Director for a five-year term

Lupin Limited announced the appointment of Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 3, 2026, and as an Independent Director for a term of five consecutive years with effect from November 3, 2026, to November 2, 2031, subject to member approval. Gupta, a Chartered Accountant with extensive experience including a previous role as Vice Chairman of Bharti Enterprises Limited, currently serves as Chairman of 360 ONE WAM Limited, Coforge Limited, and Valuedrive Technologies Limited, among other positions.

1 week agoCapital Market - Live
Spotlight
Spotlight
Lupin Ltd rises for third straight session

Lupin Ltd is up for a third straight session today. The stock is quoting at Rs 2012.2, up 1.12% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.7% on the day, quoting at 23097.15. The Sensex is at 74708.52, up 0.75%. Lupin Ltd has slipped around 0.94% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 3.45% in last one month and is currently quoting at 26710.8, up 1.9% on the day. The volume in the stock stood at 3.26 lakh shares today, compared to the daily average of 6.58 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2016.8, up 1.1% on the day. Lupin Ltd is up 2.48% in last one year as compared to a 10.21% slide in NIFTY and a 22.74% slide in the Nifty Pharma index.The PE of the stock is 13.8 based on TTM earnings ending June 26.

2 weeks agoCapital Market - Live
Corporate
Corporate
Lupin Limited’s committee approved stock options for employees vesting over three years

Lupin Limited announced that its Nomination and Remuneration Committee has granted 40,157 stock options to employees of the company and its subsidiaries under the Lupin Employees Stock Option Scheme 2025, with an exercise price of Rs 2.00 per option, vesting over a three-year period beginning one year from October 19, 2026.

3 weeks agoCapital Market - Live
Corporate
Corporate
Lupin Limited to review quarterly and half-year financials at a board meeting

Lupin Limited will hold a board meeting on Tuesday, November 03, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for company insiders will be closed from Thursday, October 01, 2026, and will reopen on Friday, November 06, 2026.

3 weeks agoCapital Market - Live
Corporate
Corporate
Lupin Limited reports certificate submission to SEBI regarding share transfer agent

Lupin Limited, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, has forwarded a certificate received from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, the company’s Registrar and Share Transfer Agent, for the quarter ended September 30, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Lupin Limited will restrict trading for insiders following SEBI regulations in 2026

Lupin Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

1 month agoCapital Market - Live
Corporate
Corporate
Lupin Limited’s committee approved allotment of equity shares to employees via stock options

Lupin Limited announced that its Operations and Finance Committee has allotted 24111 fully paid-up equity shares of Rs 2/- each, following the exercise of vested options granted to employees of the company and its subsidiaries under its stock option plans, increasing the issued and paid-up share capital to Rs 91,45,79,944 consisting of 45,72,89,972 equity shares of Rs 2/- each.

1 month agoCapital Market - Live
Spotlight
Spotlight
Lupin Ltd down for fifth straight session

Lupin Ltd is down for a fifth straight session today. The stock is quoting at Rs 2104.3, down 0.02% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75160.39, down 0.55%.Lupin Ltd has lost around 8.51% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 3.18 lakh shares today, compared to the daily average of 9.12 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2110.4, up 0.24% on the day. Lupin Ltd jumped 6.29% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.The PE of the stock is 14.58 based on TTM earnings ending June 26.

2 months agoCapital Market - Live

Frequently asked questions

  1. The share price of LUPIN as on 13th November 2026 is ₹1980.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Lupin Limited (LUPIN) share are
    • Past 1 week: -0.26%
    • Past 1 month: 2.34%
    • Past 3 months: -12.00%
    • Past 6 months: -10.62%
    • Past 1 year: -3.54%
    • Past 3 years: 68.79%
    • Past 5 years: 109.61%

  3. The current dividend yield of Lupin Limited (LUPIN) is 0.91.

  4. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Limited (LUPIN) is ₹90557.73 Cr as of 13th November 2026.

  5. The 52-week high of Lupin Limited (LUPIN) is ₹2529.50 and the 52-week low is ₹1892.90.

  6. The P/E (price-to-earnings) ratio of Lupin Limited (LUPIN) is 15.70. The P/B (price-to-book) ratio is 4.02.

  7. Lupin Limited (LUPIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. You can directly buy Lupin Limited (LUPIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.